Kazia Therapeutics (NASDAQ: KZIA) updates 10.7M ADSs after website change

Rhea-AI Filing Summary

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement to its Form F-1 prospectus covering 10,700,211 American Depositary Shares (ADSs), which represent 5,350,105,500 ordinary shares. The supplement incorporates a Form 6-K describing the launch of a new corporate website.

The company has changed its primary website to www.kaziatx.com, and prior references to www.kaziatherapeutics.com in its SEC filings should now be read as referring to the new URL. The ADSs trade on the Nasdaq Capital Market under the symbol KZIA, with a last reported sale price of $13.58 per ADS on August 28, 2026. The Form 6-K is also incorporated by reference into Kazia’s effective Form F-3 registration statements.

Key Figures

ADSs covered: 10,700,211 American Depositary Shares Ordinary shares represented: 5,350,105,500 Ordinary Shares Last reported ADS price: $13.58 per ADS +1 more

4 metrics

ADSs covered 10,700,211 American Depositary Shares Number of ADSs referenced in the supplemented F-1 prospectus

Ordinary shares represented 5,350,105,500 Ordinary Shares Ordinary shares represented by the 10,700,211 ADSs

Last reported ADS price $13.58 per ADS Last reported sale price on Nasdaq Capital Market on August 28, 2026

Form F-3 file numbers 333-276091, 333-281937, 333-294392 Registration statements into which the Form 6-K is incorporated by reference

Key Terms

American Depositary Shares, prospectus supplement, Form F-1, Form F-3, +1 more

5 terms

American Depositary Shares financial

"10,700,211 American Depositary Shares representing 5,350,105,500 Ordinary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

prospectus supplement regulatory

"This prospectus supplement is being filed to update and supplement"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Form F-1 regulatory

"forms a part of our Registration Statement on Form F-1"

A Form F-1 is the document a non-U.S. company files with U.S. regulators when it wants to sell stock or other securities to U.S. investors. It lays out the company’s business, finances, risks and how the offering will work, acting like a product manual and ingredient list so investors can judge what they’re buying. For investors, it’s a key source of verified information used to compare opportunities and assess potential reward and risk.

Form F-3 regulatory

"incorporates by reference the information contained herein into the Company’s registration statements on Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

incorporates by reference regulatory

"The Company hereby incorporates by reference the information contained herein"

FAQ

What does Kazia Therapeutics (KZIA) disclose in this prospectus supplement?

Kazia Therapeutics updates its Form F-1 prospectus for 10,700,211 ADSs to incorporate an August 31, 2026 Form 6-K, which announces the launch of a new website and updates the company’s website address used in prior SEC filings.

How many securities are covered by Kazia Therapeutics’ (KZIA) updated F-1 prospectus?

The updated prospectus covers 10,700,211 American Depositary Shares, which in turn represent 5,350,105,500 ordinary shares of Kazia Therapeutics Limited.

What is the new official website URL for Kazia Therapeutics (KZIA)?

Kazia Therapeutics states that its new website is www.kaziatx.com. It further states that any prior references to www.kaziatherapeutics.com in its SEC filings should now be read to refer to www.kaziatx.com, as applicable.

On which market are Kazia Therapeutics (KZIA) ADSs listed and at what recent price?

Kazia Therapeutics’ ADSs are listed on the Nasdaq Capital Market under the symbol KZIA. The company reports a last reported sale price of $13.58 per ADS on August 28, 2026.

How is the new Form 6-K used in Kazia Therapeutics’ (KZIA) SEC registrations?

Kazia Therapeutics states that the information in this Form 6-K is incorporated by reference into its registration statements on Form F-3 with File Nos. 333-276091, 333-281937, and 333-294392, as well as into the F-1 prospectus being supplemented.

Does this Kazia Therapeutics (KZIA) filing change the risk disclosures?

The supplement directs investors to existing Risk Factors in the F-1 prospectus and the latest Form 20-F and any subsequent reports. It does not add new risk-factor text but reiterates that investing in the securities involves a high degree of risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 07:36 AM Accepted by SEC EDGAR 08/31/2026 - 07:34 AM Learn about SEC filing dates

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-292303

PROSPECTUS SUPPLEMENT

(to Prospectus dated December 23, 2025)

10,700,211 American Depositary Shares representing

5,350,105,500

Ordinary Shares

Kazia Therapeutics Limited

This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-292303), as amended, with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on August 31, 2026 (the “August 31, 2026 Form 6-K”). Accordingly, we have attached the August 31, 2026 Form 6-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On August 28, 2026, the last reported sale price of the ADSs on Nasdaq was $13.58 per ADS.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus and the “Risk Factors” in “Item 3. Key Information-D. Risk Factors” of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is August 31, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 000-29962

Kazia Therapeutics Limited.

(Exact Name of Registrant as Specified in Its Charter)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On August 28, 2026, Kazia Therapeutics Limited (the “Company”) launched a new website. The new website can be found at www.kaziatx.com.

Any prior references to the Company’s website, including references to www.kaziatherapeutics.com, in the Company’s filings with the Securities Exchange Commission (the “SEC”) should be read to refer to the new URL, www.kaziatx.com, as applicable.

The new website has been designed to provide investors, customers, and other stakeholders with enhanced access to information regarding the Company’s business, products, services, clinical trials, and corporate developments. We encourage investors, patients, business partners, researchers, and other stakeholders to review the information we post on our website, in addition to following our press releases and SEC filings.

Incorporation by Reference

The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form F-3 (File Nos. 333-276091, 333-281937 and 333-294392).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Kazia Therapeutics Limited.
Date: August 31, 2026	By:	/s/ John Friend
	Name:	John Friend
	Title:	Chief Executive Officer

2